Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs
- 362 Downloads
The avocado toxin (+)-R-persin (persin) is active at low micromolar concentrations against breast cancer cells and synergizes with the estrogen receptor modulator 4-hydroxytamoxifen. Previous studies in the estrogen receptor-positive breast cancer cell line MCF-7 indicate that persin acts as a microtubule-stabilizing agent. In the present study, we further characterize the properties of persin and several new synthetic analogues in human ovarian cancer cells. Persin and tetrahydropersin cause G2M cell cycle arrest and increase intracellular microtubule polymerization. One analog (4-nitrophenyl)-deshydroxypersin prevents cell proliferation and blocks cells in G1 of the cell cycle rather than G2M, suggesting an additional mode of action of these compounds independent of microtubules. Persin can synergize with other microtubule-stabilizing agents, and is active against cancer cells that overexpress the P-glycoprotein drug efflux pump. Evidence from Flutax-1 competition experiments suggests that while the persin binding site on β-tubulin overlaps the classical taxoid site where paclitaxel and epothilone bind, persin retains activity in cell lines with single amino acid mutations that affect these other taxoid site ligands. This implies the existence of a unique binding location for persin at the taxoid site.
KeywordsCancer Microtubule-stabilizing agent Multidrug resistance Persin Tetrahydropersin Synergy Taxoid binding site Peloruside Flutax-1
This work was supported by grants from the Cancer Society of New Zealand, Wellington Medical Research Foundation (JJF, AK, JHM), the Joy McNicoll Postgraduate Research Award in Biomedical Science (JJF), and Victoria University of Wellington (JJF, AK, JHM). We thank Dr Paraskevi Giannakkakou for the 1A9 β-tubulin mutant cell lines, and Dr Peter Northcote and Dr Jonathan Singh for the supply of the natural product peloruside A.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Chang C-F, Isogai A, Kamikado T, Murakoshi S, Sakurai A, Tamura S (1975) Isolation and structure elucidation of growth inhibitors for silkworm larvae from avocado leaves. Agric Biol Chem 39:1167–1168Google Scholar
- 2.Oelrichs PB, JNg JC, Seawright AA, Ward W, Schäffeler L, MacLeod JK (1995) Isolation and identification of a compound from avocado (Persea americana) leaves which causes necrosis of the acinar epithelium of the lactating mammary gland and the myocardium. Nat Toxins 3:344–349CrossRefPubMedGoogle Scholar
- 7.Kingsbury JM (1964) Poisonous Plants of the United States and Canada. Prentice-Hall, Inc., Englewood Cliffs, 124Google Scholar
- 9.Butt AJ, Roberts CG, Seawright AA, Oelrichs PB, MacLeod JK, Liaw TYE, Kavallaris M, Somers-Edgar TJ, Lehrbach GM, Watts CK, Sutherland RL (2006) A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 5:2300–2309CrossRefPubMedGoogle Scholar
- 11.McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, Gee JM, Sutherland RL, Musgrove EA, Burgess A, Butt AJ (2013) Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. Brit J Cancer 109:3034–3041CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Hood KA, West LM, Northcote PT, Berridge MV, Miller JH, Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 6:207−219.Google Scholar
- 30.Wilmes A, O’Sullivan D, Chan A, Chandrahasen C, Paterson I, Northcote PT, La Flamme AC, Miller JH (2011) Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol 68:117–126CrossRefPubMedGoogle Scholar
- 31.Field JJ, Calvo E, Northcote PT, Miller JH, Altmann K-H, Díaz JF (2013) Methods for studying microtubule binding site interactions: Zampanolide as a covalent binding agent. In Wilson L and Correia JJ (eds) Methods in Cell Biology, Vol 115: Microtubules In Vitro, 2nd Ed, Academic Press, Burlington, Chapter 19, pp. 303−325Google Scholar
- 33.Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, Hamel E, Giannakakou P, Miller JH (2011) Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther 10:1419–1429CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 97:2904–2909CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Ding C, Zhang Y, Chen H, Yang Z, Wild C, Ye N, Ester CD, Xiong A, White MA, Shen Q, Zhou J (2013) Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem 56:8814–8825CrossRefPubMedGoogle Scholar
- 37.Phase 1 safety study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies: https://clinicaltrials.gov/ct2/show/NCT02044861 Accessed 18 Dec 2015
- 40.Ferlini C, Raspaglio G, Mozzetti S, Martinelli E, Ferrandina G, Gallo D, Riva A, Bombardelli E, Morazzoni P, Scambia G (2003) Bcl-2 downregulation is a novel mechanism of paclitaxel resistance. P. Am. Assoc Cancer Res 44:1104–1104Google Scholar
- 42.Kowalski RJ, Giannakakou P, Gunasekera P, Longley RE, Day BW, Hamel E (1997) The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 52:613–622PubMedGoogle Scholar